Copy to clipboard 
Hyprevention raised USD $4.5 million to support U.S. commercialization of the V-STRUT Vertebral Implant. Postmarket clinical studies will be conducted to continuously show the high performance of the products to address real clinical needs.
The company has developed the STRUTPLASTY Platform intended to reinforce bone in case of fractures or impending fractures. The technology is protected by 25 patents in the United States and Europe. Two products are currently on the market and the platform will be expanded to address more anatomical sites.
In 2020, V-STRUT Vertebral Implant obtained FDA 510(k) clearance and the company established the U.S. subsidiary, Hyprevention Inc., to launch V-STRUT sales.
“STRUTPLASTY Technology is unique on the market. Hyprevention is talented to develop easy to use products with a high clinical benefit thanks to a good understanding of biomechanics and users’ needs. We are very happy by the high interest we get from the U.S. practitioners and are glad to build a success story,” said Cécile Vienney, CEO.
Source: Hyprevention
